As Mastec (MTZ) Stock Value Declined, Driehaus Capital Management Lowered Position; Martin & Company Decreased Stake in Merck & Co. (MRK) by $1.89 Million as Market Valuation Rose

June 17, 2018 - By Maria Brooks

Merck & Co., Inc. (NYSE:MRK) Logo

Martin & Company Inc decreased its stake in Merck & Co. Inc. (MRK) by 65.7% based on its latest 2018Q1 regulatory filing with the SEC. Martin & Company Inc sold 34,998 shares as the company’s stock rose 5.40% while stock markets declined. The institutional investor held 18,269 shares of the health care company at the end of 2018Q1, valued at $995,000, down from 53,267 at the end of the previous reported quarter. Martin & Company Inc who had been investing in Merck & Co. Inc. for a number of months, seems to be less bullish one the $166.88 billion market cap company. The stock increased 0.76% or $0.47 during the last trading session, reaching $62.03. About 16.46M shares traded or 47.17% up from the average. Merck & Co., Inc. (NYSE:MRK) has declined 9.15% since June 17, 2017 and is downtrending. It has underperformed by 21.72% the S&P500. Some Historical MRK News: 09/04/2018 – John Carroll: BREAKING:Merck racks up another win in wide-ranging PhIII Keytruda lung cancer study, this time as solo therapy; 09/04/2018 – Merck: Keytruda Significantly Improves Overall Survival in Study; 13/03/2018 – FDA PRIORITY REVIEW OF KEYTRUDA IN ADVANCED CERVICAL CANCER; 08/05/2018 – Merck & Co.: July Hearing Scheduled in Brand Dispute With Germany’s Merck KGaA; 07/03/2018 – MERCK & CO INC – EISAI IS ELIGIBLE TO RECEIVE MAXIMUM OF UP TO $3.97 BLN FOR ACHIEVEMENT OF MILESTONES ASSOCIATED WITH SALES OF LENVIMA; 09/04/2018 – KEYTRUDA┬« (pembrolizumab) Monotherapy Met Primary Endpoint in Phase 3 KEYNOTE-042 Study, Significantly Improving OS as First-Line Therapy in Locally Advanced or Metastatic NSCLC Patients Expressing PD-L1 in at Least 1 Percent of Tumor; 18/05/2018 – AstraZeneca hit by falling Crestor sales, higher costs; 03/05/2018 – $MRK +2%; 08/05/2018 – Merck: Lynparza Tablets Receive EU Approval for the Treatment of Platinum-Sensitive Relapsed Ovarian Cancer; 13/03/2018 – MERCK & CO INC – SBLA FOR KEYTRUDA IS BASED IN PART ON DATA FROM PHASE 2 KEYNOTE-158 TRIAL

Richard Driehaus decreased its stake in Mastec Inc (MTZ) by 25.45% based on its latest 2018Q1 regulatory filing with the SEC. Driehaus Capital Management Llc sold 12,807 shares as the company’s stock declined 9.38% with the market. The hedge fund run by Richard Driehaus held 37,517 shares of the basic industries company at the end of 2018Q1, valued at $1.77M, down from 50,324 at the end of the previous reported quarter. Driehaus Capital Management Llc who had been investing in Mastec Inc for a number of months, seems to be less bullish one the $4.11B market cap company. The stock increased 2.66% or $1.35 during the last trading session, reaching $52.15. About 1.13 million shares traded or 24.91% up from the average. MasTec, Inc. (NYSE:MTZ) has risen 18.02% since June 17, 2017 and is uptrending. It has outperformed by 5.45% the S&P500. Some Historical MTZ News: 30/04/2018 – MasTec Sees 2018 Adj EPS $3.65; 30/04/2018 – MASTEC 1Q REV. $1.4B, EST. $1.24B; 21/03/2018 – MasTec at Company Marketing Hosted By Stephens Inc. Today; 30/04/2018 – MasTec Sees 2Q Rev $1.78B; 07/05/2018 – MasTec at Barclays Americas Select Franchise Conference May 15; 29/03/2018 – MASTEC – REPURCHASES WOULD BE FUNDED FROM CASH ON HAND AND AVAILABILITY UNDER COMPANY’S REVOLVING CREDIT FACILITY; 30/04/2018 – MasTec 1Q EPS 32c; 15/05/2018 – Stelliam Investment Management Buys New 1.1% Position in MasTec; 30/04/2018 – MasTec Sees 2018 Rev $6.9B; 30/04/2018 – MasTec Sees 2Q Adj EPS $1.03

Driehaus Capital Management Llc, which manages about $12.71B and $2.83 billion US Long portfolio, upped its stake in Easterly Government Properti by 86,520 shares to 410,018 shares, valued at $8.36 million in 2018Q1, according to the filing. It also increased its holding in Dcp Midstream Lp (NYSE:DPM) by 27,330 shares in the quarter, for a total of 103,720 shares, and has risen its stake in Quinstreet Inc (NASDAQ:QNST).

Another recent and important MasTec, Inc. (NYSE:MTZ) news was published by Bizjournals.com which published an article titled: “MasTec snags $500M contract with utility in Puerto Rico” on June 05, 2018.

Since February 1, 2018, it had 0 insider purchases, and 4 sales for $4.40 million activity. de Cardenas Alberto also sold $743,190 worth of MasTec, Inc. (NYSE:MTZ) shares. 25,000 MasTec, Inc. (NYSE:MTZ) shares with value of $1.38M were sold by Apple Robert E.

Investors sentiment decreased to 0.84 in 2018 Q1. Its down 0.65, from 1.49 in 2017Q4. It fall, as 29 investors sold MTZ shares while 117 reduced holdings. 41 funds opened positions while 82 raised stakes. 61.77 million shares or 2.20% less from 63.16 million shares in 2017Q4 were reported. Morgan Stanley holds 516,212 shares. Greenwood Assoc Lc, South Carolina-based fund reported 8,134 shares. The Missouri-based Stifel Financial Corp has invested 0.01% in MasTec, Inc. (NYSE:MTZ). Paloma Partners Commerce holds 0.05% in MasTec, Inc. (NYSE:MTZ) or 62,164 shares. Loring Wolcott And Coolidge Fiduciary Advsr Llp Ma stated it has 0% of its portfolio in MasTec, Inc. (NYSE:MTZ). Blackrock invested in 0.01% or 4.70 million shares. Impax Asset Mngmt has invested 0.8% in MasTec, Inc. (NYSE:MTZ). Greystone Managed Invs Inc has 0.33% invested in MasTec, Inc. (NYSE:MTZ). Royal Financial Bank Of Canada accumulated 0% or 193,746 shares. Opus Capital Grp Ltd Liability Corporation reported 40,920 shares or 0.48% of all its holdings. Suffolk Capital Limited Liability Corp stated it has 0.13% of its portfolio in MasTec, Inc. (NYSE:MTZ). Quantitative Systematic Strategies Limited Company invested 0.05% of its portfolio in MasTec, Inc. (NYSE:MTZ). Rothschild Asset Mngmt accumulated 854,522 shares. Quantitative Management Limited Liability stated it has 0.07% of its portfolio in MasTec, Inc. (NYSE:MTZ). 1.15M were reported by Glenmede Trust Comm Na.

Among 15 analysts covering MasTec (NYSE:MTZ), 13 have Buy rating, 0 Sell and 2 Hold. Therefore 87% are positive. MasTec had 57 analyst reports since August 3, 2015 according to SRatingsIntel. KeyBanc Capital Markets maintained the stock with “Buy” rating in Monday, November 20 report. On Friday, October 13 the stock rating was maintained by Stifel Nicolaus with “Buy”. KeyBanc Capital Markets maintained the shares of MTZ in report on Monday, September 18 with “Buy” rating. The rating was maintained by Citigroup on Tuesday, February 6 with “Buy”. The firm has “Buy” rating by Stifel Nicolaus given on Friday, January 26. The firm has “Market Perform” rating given on Friday, November 18 by Avondale. The rating was maintained by Robert W. Baird with “Buy” on Wednesday, January 3. The stock of MasTec, Inc. (NYSE:MTZ) has “Buy” rating given on Thursday, March 1 by Craig Hallum. The company was maintained on Tuesday, September 5 by Robert W. Baird. The stock has “Buy” rating by B. Riley & Co on Tuesday, November 7.

Analysts await MasTec, Inc. (NYSE:MTZ) to report earnings on August, 2. They expect $1.00 earnings per share, up 1.01% or $0.01 from last year’s $0.99 per share. MTZ’s profit will be $78.77M for 13.04 P/E if the $1.00 EPS becomes a reality. After $0.32 actual earnings per share reported by MasTec, Inc. for the previous quarter, Wall Street now forecasts 212.50% EPS growth.

Martin & Company Inc, which manages about $1.98 billion and $300.36 million US Long portfolio, upped its stake in Mckesson Corp. (NYSE:MCK) by 6,203 shares to 23,493 shares, valued at $3.31M in 2018Q1, according to the filing. It also increased its holding in Consolidated Communications Ho (NASDAQ:CNSL) by 75,455 shares in the quarter, for a total of 158,672 shares, and has risen its stake in Zix Corp. (NASDAQ:ZIXI).

Analysts await Merck & Co., Inc. (NYSE:MRK) to report earnings on July, 27. They expect $1.04 earnings per share, up 2.97% or $0.03 from last year’s $1.01 per share. MRK’s profit will be $2.80 billion for 14.91 P/E if the $1.04 EPS becomes a reality. After $1.05 actual earnings per share reported by Merck & Co., Inc. for the previous quarter, Wall Street now forecasts -0.95% negative EPS growth.

Investors sentiment increased to 1 in Q1 2018. Its up 0.06, from 0.94 in 2017Q4. It is positive, as 72 investors sold MRK shares while 603 reduced holdings. 114 funds opened positions while 561 raised stakes. 1.91 billion shares or 1.08% less from 1.93 billion shares in 2017Q4 were reported. Goelzer Investment Mgmt Inc reported 187,361 shares. Delaware-based Dupont Mgmt Corporation has invested 0.46% in Merck & Co., Inc. (NYSE:MRK). Moreover, State Bank Of Nova Scotia has 0.28% invested in Merck & Co., Inc. (NYSE:MRK). Chesapeake Asset Management Ltd Liability Corp invested 4% in Merck & Co., Inc. (NYSE:MRK). Miller Howard Investments invested 1.81% in Merck & Co., Inc. (NYSE:MRK). Sageworth Tru has 206 shares for 0% of their portfolio. Invesco has 19.56M shares. Smead Mgmt reported 1.08M shares or 2.84% of all its holdings. St Germain D J Company holds 15,872 shares or 0.11% of its portfolio. Wealthcare Cap Management Limited Liability Co stated it has 455 shares. Parsons Cap Ri, Rhode Island-based fund reported 98,466 shares. Georgia-based Rowland And Counsel Adv has invested 0% in Merck & Co., Inc. (NYSE:MRK). Bainco International Invsts has 156,697 shares. Advisory Ser Net Ltd Liability Co reported 0.24% stake. Stillwater Capital Advisors Lc, Pennsylvania-based fund reported 249,416 shares.

More recent Merck & Co., Inc. (NYSE:MRK) news were published by: Finance.Yahoo.com which released: “7 Perfect Dividend Stocks” on June 16, 2018. Also Seekingalpha.com published the news titled: “Avoiding The ‘Black Hole’ Of Disease Development” on June 15, 2018. 247Wallst.com‘s news article titled: “Merck Wins Another FDA Approval For Keytruda” with publication date: June 14, 2018 was also an interesting one.

Among 24 analysts covering Merck & Co. Inc. (NYSE:MRK), 21 have Buy rating, 0 Sell and 3 Hold. Therefore 88% are positive. Merck & Co. Inc. had 90 analyst reports since August 13, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Friday, November 3 by Cowen & Co. The rating was maintained by Jefferies on Friday, April 15 with “Hold”. The stock has “Overweight” rating by Piper Jaffray on Thursday, January 12. The stock of Merck & Co., Inc. (NYSE:MRK) earned “Buy” rating by Goldman Sachs on Monday, April 23. On Tuesday, April 17 the stock rating was upgraded by Morgan Stanley to “Overweight”. The firm earned “Hold” rating on Tuesday, January 16 by Jefferies. The stock of Merck & Co., Inc. (NYSE:MRK) earned “Market Perform” rating by Cowen & Co on Wednesday, April 12. The firm earned “Outperform” rating on Wednesday, August 30 by Credit Suisse. As per Friday, July 28, the company rating was maintained by Piper Jaffray. Morgan Stanley upgraded the stock to “Overweight” rating in Thursday, January 12 report.

Merck & Co., Inc. (NYSE:MRK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.